AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Senti Biosciences Inc (NASDAQ:SNTI)
0.9317 USD
-0.019 2.009%| Previous Close (in USD) | 0.9508 |
|---|---|
| Change | -0.019 2.009% |
| 52 W H/L (in USD) | 1.100/0.270 |
| EBITDA (in USD) | -60.881M |
| PE Ratio | -- |
| Volume | 114918 |
| Diluted Eps TTM | -1.73 |
| Total Assets (in USD) | 119.484M |
|---|---|
| Total Liabilities (in USD) | 52.571M |
| Revenue TTM (in USD) | 2.561M |
| Cash (in USD) | 35.926M |
| Market Cap (in USD) | 14.770 M |
| Revenue Per Share TTM | 0.058 |
| Gross Profit TTM (in USD) | -29.781M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Senti Biosciences Inc
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
2 Corporate Drive, South San Francisco, CA, United States, 94080
650 239 2030
Employees: 48
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Timothy K. Lu M.D., Ph.D. | Co-founder, CEO, Pres & Director | 1981 |
| 2. | Dr. Philip Lee Ph.D. | Co-Founder & CTO | 1982 |
| 3. | Ms. Susan D. Berland | Sr. Financial Exec. & Independent Director | 1955 |
| 4. | Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director | 1966 |
| 5. | Dr. Wilson Wong Ph.D. | Scientific Co-Founder & Member of Scientific Advisory Board | NA |
| 6. | Dr. Deborah A. Knobelman Ph.D. | CFO & Treasurer | 1974 |
| 7. | Dr. Kanya Rajangam M.D., Ph.D. | Chief Medical & Devel. Officer | 1973 |
| 8. | Susan Kahlert | Controller | NA |
| 9. | Dr. Timothy K. Lu M.D., Ph.D. | Co-founder, CEO, President & Director | 1981 |
| 10. | Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director | 1967 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -58.21M | -55.319M | -19.862M | - |
| Minority Interest | - | - | - | - |
| Net Income | -45.791M | -55.33M | -20.012M | - |
| Selling General Administrative | 40.848M | 21.25M | 9.304M | - |
| Gross Profit | 4.286M | 2.291M | 0.394M | - |
| Reconciled Depreciation | 3.92M | 3.01M | 1.985M | - |
| Ebit | -74.549M | -40.446M | -24.694M | -21.782M |
| Ebitda | -70.629M | -37.414M | -22.471M | - |
| Depreciation And Amortization | 3.92M | 3.032M | 2.223M | - |
| Operating Income | -70.629M | -40.446M | -24.694M | - |
| Other Operating Expenses | 74.915M | 42.737M | 25.088M | - |
| Interest Expense | -3.92M | 0.011M | 0.088M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | 1.701M | 0.011M | 0.088M | - |
| Net Interest Income | 1.701M | 0.011M | 0.088M | - |
| Income Tax Expense | -12.419M | 0.011M | 0.15M | - |
| Total Revenue | 4.286M | 2.291M | 0.394M | - |
| Total Operating Expenses | 74.915M | 42.737M | 25.088M | - |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 12.419M | -14.873M | 4.832M | - |
| Net Income From Continuing Ops | -58.21M | -55.319M | -19.862M | - |
| Net Income Applicable To Common Shares | -58.21M | -55.319M | -19.862M | -21.157M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 119.484M | 180.792M | 96.702M | 48.345M | - |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 17.57M | 0.101M | 1.073M | 0.83M | - |
| Total Liab | 52.571M | 53.529M | 208.159M | 107.058M | - |
| Total Stockholder Equity | 66.913M | 127.263M | -111.457M | -58.713M | - |
| Other Current Liab | 6.305M | 12.999M | 5.957M | 0.435M | 0.165M |
| Common Stock | 0.005M | 0.004M | 0.001M | 0.001M | 0.001M |
| Capital Stock | 0.005M | 0.004M | 0.001M | 0.001M | - |
| Retained Earnings | -244.344M | -173.286M | -115.076M | -59.757M | -39.895M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 3.659M | 3.433M | 0.497M | 0.497M |
| Cash | 35.926M | 57.621M | 56.034M | 30.537M | - |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 12.672M | 18.053M | 14.543M | 4.866M | 4.306M |
| Current Deferred Revenue | 0.989M | 0.799M | 1.656M | 1.998M | - |
| Net Debt | 1.74M | -20.53M | -33.303M | -16.488M | - |
| Short Term Debt | 4.128M | 1.988M | 1.743M | 1.519M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 37.666M | 37.091M | 22.731M | 14.049M | - |
| Other Stockholder Equity | 311.252M | 119.752M | 3.618M | 1.043M | 0.013M |
| Property Plant Equipment | - | 56.136M | 33.076M | 16.139M | 16.585M |
| Total Current Assets | 71.2M | 102.579M | 60.193M | 31.709M | 18.76M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 40.942M | - | - | - |
| Net Receivables | 17.704M | 0.626M | 0.483M | 0.317M | 0.078M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | 3.289M | 2.603M | 0.025M | - |
| Accounts Payable | 1.25M | 2.267M | 5.187M | 0.914M | 1.197M |
| Accumulated Other Comprehensive Income | -119.484M | 0.001M | - | - | - |
| Non Currrent Assets Other | 2.031M | 3.659M | 3.433M | 0.497M | - |
| Non Current Assets Total | 48.284M | 78.213M | 36.509M | 16.636M | - |
| Capital Lease Obligations | 37.666M | 37.091M | 22.731M | 14.049M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -40.585M | -5.543M | 12.519M | 5.732M |
| Total Cashflows From Investing Activities | -81.959M | -5.543M | 11.358M | 3.751M |
| Total Cash From Financing Activities | 118.551M | 68.435M | 38.051M | 14.012M |
| Net Income | -58.222M | -55.319M | -19.862M | -21.157M |
| Change In Cash | 1.696M | 28.257M | 25.236M | -0.615M |
| Begin Period Cash Flow | 59.291M | 31.034M | 5.798M | - |
| End Period Cash Flow | 60.987M | 59.291M | 31.034M | 5.798M |
| Total Cash From Operating Activities | -34.896M | -34.635M | -24.173M | -18.378M |
| Depreciation | 3.92M | 3.01M | 1.985M | 1.396M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | 0.004M | - | - |
| Change To Inventory | - | -0.205M | -1.606M | - |
| Sale Purchase Of Stock | 0.196M | - | - | - |
| Other Cashflows From Financing Activities | 117.627M | 68.435M | 38.051M | -0.019M |
| Capital Expenditures | 41.374M | 5.543M | 1.161M | 1.996M |
| Change In Working Capital | 13.904M | 0.615M | -1.775M | - |
| Other Non Cash Items | -10.89M | 14.742M | -5.028M | - |
| Free Cash Flow | -76.27M | -40.178M | -25.334M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Genomic Revolution ETF | 2 years ago | 1859457 |
| 2. | ARK Genomic Revolution | 2 years ago | 1843710 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 386899 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 320153 |
| 5. | Bridgeway Ultra-Small Company Market | 2 years ago | 145000 |
| 6. | Fidelity Extended Market Index | 2 years ago | 132043 |
| 7. | Fidelity Total Market Index | 2 years ago | 38123 |
| 8. | BlackRock Extended Mkt Composite | 2 years ago | 37424 |
| 9. | BlackRock Extended Equity Market K | 2 years ago | 32661 |
| 10. | Fidelity Series Total Market Index | 2 years ago | 31578 |
| 11. | Fidelity Nasdaq Composite Index | 2 years ago | 28123 |
| 12. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 22552 |
| 13. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 18112 |
| 14. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 14296 |
| 15. | Northern Trust Extended Eq Market Idx | 2 years ago | 14296 |
| 16. | Spartan Total Market Index Pool E | 2 years ago | 11365 |
| 17. | T. Rowe Price Hlth Sci Eq Q | 2 years ago | 10616 |
| 18. | BMO ARK Genomic Revolution Series F | 2 years ago | 5659 |
| 19. | Spartan Extended Market Index Pool E | 2 years ago | 4204 |
| 20. | Extended Equity Market Fund M | 2 years ago | 4029 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | NEA Management Company, LLC | 2 years ago | 4426151 |
| 2. | 8VC GP I LLC | 2 years ago | 2537558 |
| 3. | ARK Investment Management LLC | 2 years ago | 1630922 |
| 4. | Vanguard Group Inc | 2 years ago | 707052 |
| 5. | Intel Corp | 2 years ago | 595665 |
| 6. | Hongkou Capital LP | 2 years ago | 310533 |
| 7. | Geode Capital Management, LLC | 2 years ago | 238406 |
| 8. | Bridgeway Capital Management, LLC | 2 years ago | 145000 |
| 9. | Two Sigma Investments LLC | 2 years ago | 93621 |
| 10. | Artal Group S A | 2 years ago | 55555 |
| 11. | BlackRock Inc | 2 years ago | 40052 |
| 12. | State Street Corporation | 2 years ago | 39100 |
| 13. | Northern Trust Corp | 2 years ago | 36848 |
| 14. | XTX Topco Ltd | 2 years ago | 21645 |
| 15. | Allen Operations LLC | 2 years ago | 21443 |
| 16. | Virtu Financial LLC | 2 years ago | 19678 |
| 17. | HARBOUR INVESTMENTS, INC. | 2 years ago | 15000 |
| 18. | Millennium Management LLC | 2 years ago | 13337 |
| 19. | Bank of New York Mellon Corp | 2 years ago | 12369 |
| 20. | Bank of America Corp | 2 years ago | 5241 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...